Clinical symptoms:

The objective of therapeutic apheresis using immunoadsorbers is to remove pathogenic antibodies or auto-antibodies and circulating immune complexes from the patient’s plasma. These are very significant in the progress of immunological diseases. Immunoadsorption is therefore used as a therapeutic measure in the treatment of some autoimmune diseases or antibody-mediated transplant rejection. The adsorber systems used in immunoadsorption can differ, among other things, in their ligands and other characteristics. Fresenius Medical Care Adsorber Tec GmbH produces 4 different kinds of immunoadsorber. All of these can only be used with plasma, so the plasma must always be separated before they are used. (Source: Fresenius brochure “Immunoadsorption in dilated cardiomyophathy (DCM)” and “Globaffin – the first synthetic broadband immunoadsorber”)

Adsorber: Immunosorba®

The Immunosorba® adsorber contains Protein A as a ligand. This is a protein from the cell wall of the bacterium Staphylococcus aureus, which has a high binding affinity to the constant (Fc-) segment, especially IgG-class antibodies. Two adsorbers always work in alternation during the treatment in order to remove as many antibodies as possible. While one adsorbs, the other desorbs (= regenerates) and vice versa. This regeneration can take place as often as needed during treatment. After treatment, the adsorbers are preserved and used on the same patient as often as needed. (Source: Fresenius brochure “Immunoadsorption: effective treatment of autoimmune diseases”)

Adsorber: GLOBAFFIN®

The immunoadsorber GLOBAFFIN® is the first synthetic broadband immunoadsorber and contains the synthetic peptide GAM® as a ligand. It is thus completely free of animal materials. The peptide has a high binding affinity with antibodies (mainly IgG-class). GLOBAFFIN is also used as a duo and preserved after treatment for the next session. (Source: Fresenius brochure “Globaffin – the first synthetic broadband immunoadsorber”)

Adsorber: LIGASORB*

A “single-use” adsorber, approved in 2015, was developed for immunoadsorption in acute autoimmune disease. LIGASORB contains a recombinant A protein (produced using gene technology) as a ligand. One adsorber, which is regenerated multiple times during the treatment, is used per treatment. This allows a high level of binding of antibodies similar to the use of a double column, but the adsorber is not preserved after the treatment. LIGASORB is disposed of immediately after the treatment.

*Product is currently not available

Adsorber: IgEnio®

A new adsorber has been developed for the treatment of IgE-induced (immunoglobulin E) diseases. IgEnio® is a single-use adsorber which selectively decreases the IgE level in the blood plasma in a single pass. Recent epidemiological data indicate that IgE-induced diseases affect more than 25 percent of the world population. It is estimated that 10 percent of this group suffer severe allergic symptoms such as asthma and atopic dermatitis. IgEnio® offers these patients another therapeutic option. (Source: Fresenius brochure “IgEnio – a novel treatment option for removing IgE”)